IKNA

Ikena Oncology, Inc.

1.40 USD
-0.03 (-2.10%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Ikena Oncology, Inc. stock is up 11.11% since 30 days ago. The next earnings date is Aug 8, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 75% of the previous 3 May’s closed higher than April. 100% of analysts rate it a buy.

About Ikena Oncology, Inc.

Ikena Oncology, Inc. focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway.